Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer

Reike M, Juette H, Wirtz R, Erben P, Tully K, Eckstein M, Weyerer V, Hartmann A, Kriegmair M, Wezel F, Bolenz C, Tannapfel A, Noldus J, Roghmann F (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Journal of Clinical Oncology American Society of Clinical Oncology

Publisher: AMER SOC CLINICAL ONCOLOGY

City/Town: ALEXANDRIA

Conference Proceedings Title: JOURNAL OF CLINICAL ONCOLOGY

Event location: San Francisco, CA

DOI: 10.1200/jco.2020.38.6_suppl.530

Authors with CRIS profile

Markus Eckstein Institute of Pathology Veronika Bahlinger Institute of Pathology Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Involved external institutions

Ruhr-Universität Bochum (RUB)

Germany (DE) St. Elisabeth Gruppe GmbH - Katholische Kliniken Rhein-Ruhr

Germany (DE) STRATIFYER Molecular Pathology GmbH

Germany (DE) Universitätsklinikum Ulm

Germany (DE) Ruprecht-Karls-Universität Heidelberg

Germany (DE) Universität Ulm

Germany (DE)

How to cite

APA:

Reike, M., Juette, H., Wirtz, R., Erben, P., Tully, K., Eckstein, M.,... Roghmann, F. (2020). Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer. In JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA, US: ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

MLA:

Reike, Moritz, et al. "Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer." Proceedings of the Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY, 2020.

BibTeX: Download